An analysis of Moderna's newly approved mRNA influenza vaccine and the evidence on its efficacy, safety, and reformulation advantages for seasonal flu control.
Key Takeaways
- Study also found that mFLUSIVA was well tolerated by most participants
- Adverse side effects were predominantly mild to moderate
- It measured participants’ antibody responses to flu rather than flu-like symptoms